-
公开(公告)号:US20120289502A1
公开(公告)日:2012-11-15
申请号:US13558325
申请日:2012-07-25
申请人: Naoto Osakada , Mariko Osakada , Takashi Sawada , Satoshi Kaneko , Atsuko Mizutani , Noriaki Uesaka , Yoshisuke Nakasato , Keishi Katayama , Masamori Sugawara , Yushi Kitamura
发明人: Naoto Osakada , Mariko Osakada , Takashi Sawada , Satoshi Kaneko , Atsuko Mizutani , Noriaki Uesaka , Yoshisuke Nakasato , Keishi Katayama , Masamori Sugawara , Yushi Kitamura
IPC分类号: A61K31/4164 , A61P25/00 , A61K31/5377 , A61K31/4439 , A61K31/454
CPC分类号: C07D233/64 , C07D401/04 , C07D405/06 , C07D405/14 , C07D409/14 , C07D413/14 , C07D417/14 , C07D471/04
摘要: A CB2 receptor modulator comprising an imidazole derivative represented by the general formula (I): [wherein, R1 represents optionally substituted lower alkyl or the like; R2 represents optionally substituted cycloalkyl or the like; R3 represents optionally substituted aryl or the like; and n represents an integer of 0 to 3] or a pharmaceutically acceptable salt thereof as an active ingredient, and the like are provided.
摘要翻译: 包含由通式(I)表示的咪唑衍生物的CB2受体调节剂:[其中,R 1表示任选取代的低级烷基等; R2代表任选取代的环烷基等; R3表示任选取代的芳基等; 和n表示0〜3的整数]或其药学上可接受的盐作为活性成分,等。
-
公开(公告)号:US08236841B2
公开(公告)日:2012-08-07
申请号:US12310926
申请日:2007-09-13
申请人: Takashi Sawada , Naoto Osakada , Satoshi Kaneko , Atsuko Mizutani , Noriaki Uesaka , Keishi Katayama
发明人: Takashi Sawada , Naoto Osakada , Satoshi Kaneko , Atsuko Mizutani , Noriaki Uesaka , Keishi Katayama
IPC分类号: A01N43/52 , A01N43/54 , A01N43/90 , A61K31/415 , A61K31/517 , A61K31/519 , C07D235/00 , C07D487/00
CPC分类号: C07D471/04 , C07D487/04
摘要: A fused heterocycle derivative represented by the general formula (I): (wherein R1 represents optionally substituted lower alkyl, or the like; R2 represents an optionally substituted aliphatic heterocyclic group, or the like; R3 represents —C(═Z)NR5R6 (wherein R5 and R6 represent optionally substituted lower alkyl, or the like, and Z represents an oxygen atom or the like), or the like; n represents an integer of 1 to 3; and W represents C—R5 (wherein R5 represents a hydrogen atom or the like)) or a pharmaceutically acceptable salt thereof, and the like are provided.
摘要翻译: 由通式(I)表示的稠合杂环衍生物:其中R 1表示任选取代的低级烷基等; R 2表示任选取代的脂族杂环基等; R 3表示-C(= Z)NR 5 R 6(其中 R 5和R 6表示任选取代的低级烷基等,Z表示氧原子等)等; n表示1〜3的整数,W表示C-R5(式中,R5表示氢原子 等))或其药学上可接受的盐等。
-
公开(公告)号:US08273738B2
公开(公告)日:2012-09-25
申请号:US12440237
申请日:2007-09-05
申请人: Naoto Osakada , Mariko Osakada , Takashi Sawada , Satoshi Kaneko , Atsuko Mizutani , Noriaki Uesaka , Yoshisuke Nakasato , Keishi Katayama , Masamori Sugawara , Yushi Kitamura
发明人: Naoto Osakada , Mariko Osakada , Takashi Sawada , Satoshi Kaneko , Atsuko Mizutani , Noriaki Uesaka , Yoshisuke Nakasato , Keishi Katayama , Masamori Sugawara , Yushi Kitamura
IPC分类号: A61K31/535 , A61K31/4965
CPC分类号: C07D233/64 , C07D401/04 , C07D405/06 , C07D405/14 , C07D409/14 , C07D413/14 , C07D417/14 , C07D471/04
摘要: A CB2 receptor modulator comprising an imidazole derivative represented by the general formula (I): [wherein, R1 represents optionally substituted lower alkyl or the like; R2 represents optionally substituted cycloalkyl or the like; R3 represents optionally substituted aryl or the like; and n represents an integer of 0 to 3] or a pharmaceutically acceptable salt thereof as an active ingredient, and the like are provided.
摘要翻译: 包含由通式(I)表示的咪唑衍生物的CB2受体调节剂:[其中,R 1表示任选取代的低级烷基等; R2代表任选取代的环烷基等; R3表示任选取代的芳基等; 和n表示0〜3的整数]或其药学上可接受的盐作为活性成分,等。
-
公开(公告)号:US20100152178A1
公开(公告)日:2010-06-17
申请号:US12440237
申请日:2007-09-05
申请人: Naoto Osakada , Mariko Osakada , Takashi Sawada , Satoshi Kaneko , Atsuko Mizutani , Noriaki Uesaka , Yoshisuke Nakasato , Keishi Katayama , Masamori Sugawara , Yushi Kitamura
发明人: Naoto Osakada , Mariko Osakada , Takashi Sawada , Satoshi Kaneko , Atsuko Mizutani , Noriaki Uesaka , Yoshisuke Nakasato , Keishi Katayama , Masamori Sugawara , Yushi Kitamura
IPC分类号: A61K31/5377 , C07D233/64 , A61K31/4174 , C07D401/04 , A61K31/4439 , C07D401/10 , A61K31/454 , C07D413/10 , C07D471/04 , A61K31/519 , C07D401/14 , A61K31/497 , C07D413/14 , A61P29/00 , A61P25/06 , A61P25/00 , A61P37/08 , A61P37/00 , A61P19/02 , A61P1/00 , A61P25/28 , A61P11/06 , A61P11/00 , A61P17/00 , A61P9/10 , A61P3/04 , A61P19/10 , A61P27/06
CPC分类号: C07D233/64 , C07D401/04 , C07D405/06 , C07D405/14 , C07D409/14 , C07D413/14 , C07D417/14 , C07D471/04
摘要: A CB2 receptor modulator comprising an imidazole derivative represented by the general formula (I): [wherein, R1 represents optionally substituted lower alkyl or the like; R2 represents optionally substituted cycloalkyl or the like; R3 represents optionally substituted aryl or the like; and n represents an integer of 0 to 3] or a pharmaceutically acceptable salt thereof as an active ingredient, and the like are provided.
摘要翻译: 包含由通式(I)表示的咪唑衍生物的CB2受体调节剂:[其中,R 1表示任选取代的低级烷基等; R2代表任选取代的环烷基等; R3表示任选取代的芳基等; 和n表示0〜3的整数]或其药学上可接受的盐作为活性成分,等。
-
公开(公告)号:US20090239853A1
公开(公告)日:2009-09-24
申请号:US12310926
申请日:2007-09-13
申请人: Takashi Sawada , Naoto Osakada , Satoshi Kaneko , Atsuko Mizutani , Noriaki Uesaka , Keishi Katayama
发明人: Takashi Sawada , Naoto Osakada , Satoshi Kaneko , Atsuko Mizutani , Noriaki Uesaka , Keishi Katayama
IPC分类号: A61K31/541 , C07D471/04 , A61K31/437 , A61K31/519 , C07D487/04 , A61P25/00
CPC分类号: C07D471/04 , C07D487/04
摘要: A fused heterocycle derivative represented by the general formula (I): (wherein R1 represents optionally substituted lower alkyl, or the like; R2 represents an optionally substituted aliphatic heterocyclic group, or the like; R3 represents —C(=Z)NR5R6 (wherein R5 and R6 represent optionally substituted lower alkyl, or the like, and Z represents an oxygen atom or the like), or the like; n represents an integer of 1 to 3; and W represents C—R5 (wherein R5 represents a hydrogen atom or the like)) or a pharmaceutically acceptable salt thereof, and the like are provided.
摘要翻译: 由通式(I)表示的稠合杂环衍生物:(其中R 1表示任选取代的低级烷基等; R 2表示任选取代的脂族杂环基等; R 3表示-C(= Z)NR 5 R 6(其中 R 5和R 6表示任选取代的低级烷基等,Z表示氧原子等)等; n表示1〜3的整数,W表示C-R5(式中,R5表示氢原子 等))或其药学上可接受的盐等。
-
公开(公告)号:US09000186B2
公开(公告)日:2015-04-07
申请号:US13983248
申请日:2012-02-01
申请人: Takashi Sawada , Tomohiro Danjo , Keiichi Motosawa , Takayuki Furuta , Maki Ichioka , Masamori Sugawara , Noriaki Uesaka
发明人: Takashi Sawada , Tomohiro Danjo , Keiichi Motosawa , Takayuki Furuta , Maki Ichioka , Masamori Sugawara , Noriaki Uesaka
IPC分类号: C07D235/02 , C07D471/04 , A61K31/4184 , A61K31/42 , A61K31/4355 , A61K31/4439 , A61K31/4525 , A61K31/497 , A61K31/519 , C07D487/04 , C07D519/00
CPC分类号: C07D471/04 , A61K31/4184 , A61K31/42 , A61K31/4355 , A61K31/4439 , A61K31/4525 , A61K31/497 , A61K31/519 , C07D487/04 , C07D519/00
摘要: A ring-fused heterocyclic derivative represented by the following general formula (I) or a pharmaceutically acceptable salt thereof having a T-type calcium channel regulatory effect and useful as a pruritus therapeutic and/or preventive agent, and the like are provided. In the general formula (I), R1 represents optionally substituted lower alkyl, and the like; R2 represents an optionally substituted cycloalkyl, and the like; Q represents a hydrogen atom, and the like; R3 represents —C(═O)NR8R9 (wherein R8 and R9 may be the same or different, and each represents a hydrogen atom, and the like), and the like; L1 represents —CR11AR11B— (wherein R11A and R11B may be the same or different, and each represents a hydrogen atom, and the like), and the like; and W1 and W2 may be the same or different, and each represents C—R12 (wherein R12 represents a hydrogen atom, and the like), and the like.
摘要翻译: 提供由具有T型钙通道调节作用并可用作瘙痒治疗和/或预防剂的由以下通式(I)表示的环稠合杂环衍生物或其药学上可接受的盐。 在通式(I)中,R 1表示任选取代的低级烷基等; R2表示任选取代的环烷基等; Q表示氢原子等; R 3表示-C(= O)NR 8 R 9(其中R 8和R 9可以相同或不同,各自表示氢原子等)等。 L1表示-CR11AR11B-(其中R11A和R11B可以相同或不同,各自表示氢原子等)等。 并且W1和W2可以相同或不同,并且各自表示C-R12(其中R12表示氢原子等)等。
-
公开(公告)号:US20140038941A1
公开(公告)日:2014-02-06
申请号:US13983248
申请日:2012-02-01
申请人: Takashi Sawada , Tomohiro Danjo , Keiichi Motosawa , Takayuki Furuta , Maki Ichioka , Masamori Sugawara , Noriaki Uesaka
发明人: Takashi Sawada , Tomohiro Danjo , Keiichi Motosawa , Takayuki Furuta , Maki Ichioka , Masamori Sugawara , Noriaki Uesaka
IPC分类号: C07D471/04 , C07D519/00 , C07D487/04
CPC分类号: C07D471/04 , A61K31/4184 , A61K31/42 , A61K31/4355 , A61K31/4439 , A61K31/4525 , A61K31/497 , A61K31/519 , C07D487/04 , C07D519/00
摘要: A ring-fused heterocyclic derivative represented by the following general formula (I) or a pharmaceutically acceptable salt thereof having a T-type calcium channel regulatory effect and useful as a pruritus therapeutic and/or preventive agent, and the like are provided. In the general formula (I), R1 represents optionally substituted lower alkyl, and the like; R2 represents an optionally substituted cycloalkyl, and the like; Q represents a hydrogen atom, and the like; R3 represents —C(═O)NR8R9 (wherein R8 and R9 may be the same or different, and each represents a hydrogen atom, and the like), and the like; L1 represents —CR11AR11B— (wherein R11A and R11B may be the same or different, and each represents a hydrogen atom, and the like), and the like; and W1 and W2 may be the same or different, and each represents C—R12 (wherein R12 represents a hydrogen atom, and the like), and the like.
摘要翻译: 提供由具有T型钙通道调节作用并可用作瘙痒治疗和/或预防剂的由以下通式(I)表示的环稠合杂环衍生物或其药学上可接受的盐。 在通式(I)中,R 1表示任选取代的低级烷基等; R2表示任选取代的环烷基等; Q表示氢原子等; R 3表示-C(= O)NR 8 R 9(其中R 8和R 9可以相同或不同,各自表示氢原子等)等。 L1表示-CR11AR11B-(其中R11A和R11B可以相同或不同,各自表示氢原子等)等。 并且W1和W2可以相同或不同,并且各自表示C-R12(其中R12表示氢原子等)等。
-
公开(公告)号:US20120101101A1
公开(公告)日:2012-04-26
申请号:US13266152
申请日:2010-04-28
申请人: Noriaki Uesaka , Takashi Sawada , Tomoyuki Kanda
发明人: Noriaki Uesaka , Takashi Sawada , Tomoyuki Kanda
IPC分类号: A61K31/5377 , A61K31/506 , A61K31/427 , A61K31/4355 , A61K31/4709 , A61K31/436 , A61K31/435 , A61K31/4365 , C07D417/14 , C07D491/048 , C07D491/052 , C07D495/04 , A61P25/14 , A61P25/16 , A61K31/4439
CPC分类号: C07D495/04 , A61K31/198 , A61K31/427 , A61K31/435 , A61K31/4355 , A61K31/436 , A61K31/4365 , A61K31/4439 , A61K31/4709 , A61K31/506 , A61K31/5377 , C07D417/14 , C07D491/048 , C07D491/052
摘要: Provided are an agent for the treatment and/or prophylaxis of a movement disorder, the agent for the treatment and/or prophylaxis wherein the movement disorder is extrapyramidal syndrome, the agent for the treatment and/or prophylaxis wherein the movement disorder is bradykinesia, gait disturbance, dystonia, dyskinesia or tardive dyskinesia, the agent for the treatment and/or prophylaxis wherein the movement disorder is a side effect of L-DOPA and/or dopamine agonist therapy, and the like, each containing a thiazole derivative represented by the formula (I) wherein R1 represents aryl and the like, and R2 represents pyridyl or the like, or a pharmaceutically acceptable salt thereof as an active ingredient.
摘要翻译: 提供用于治疗和/或预防运动障碍的药物,用于治疗和/或预防的药物,其中运动障碍是锥体外系综合征,用于治疗和/或预防的药物,其中运动障碍是运动障碍,步态 干扰,肌张力障碍,运动障碍或迟发性运动障碍,其中运动障碍是L-DOPA和/或多巴胺激动剂治疗的副作用的治疗和/或预防药物等,每种含有式 (I)其中R1表示芳基等,R2表示吡啶基等,或其药学上可接受的盐作为有效成分。
-
公开(公告)号:US20100280023A1
公开(公告)日:2010-11-04
申请号:US11917972
申请日:2006-06-23
IPC分类号: A61K31/537 , A61K31/427 , C07D417/14 , A61K31/5377 , A61K31/4439 , A61P25/00 , A61P25/16 , A61P25/28 , A61P25/24 , A61P9/10
CPC分类号: C07D491/08 , C07D417/04 , C07D417/14 , C07D493/08 , C07D493/10
摘要: It is intended to provide an adenosine A2A receptor antagonist containing as an active ingredient a thiazole derivative represented by the general formula (I) [in the formula, R1 represents a substituted or unsubstituted five-membered aromatic heterocyclic group containing at least one oxygen atom, R2 represents a substituted or unsubstituted heterocyclic group, —COR6 (in the formula, R6 represents a substituted or unsubstituted heterocyclic group, a substituted or unsubstituted aromatic heterocyclic group or the like) or the like, R3 represents the general formula (II), —NHCOR (in the formula, R7 represents —NR8R9 or the like) or the like], or a pharmacologically acceptable salt thereof, etc. (I) (II)
摘要翻译: 本发明提供一种含有作为活性成分的通式(I)表示的噻唑衍生物的腺苷A 2A受体拮抗剂[式中,R 1表示取代或未取代的含有至少一个氧原子的5元芳族杂环基, R2表示取代或未取代的杂环基,-COR6(式中,R6表示取代或未取代的杂环基,取代或未取代的芳香族杂环基等)等,R3表示通式(II), - NHCOR(式中,R7表示-NR8R9等)或其药理学上可接受的盐等。(I)(II)
-
公开(公告)号:US07718808B2
公开(公告)日:2010-05-18
申请号:US10584633
申请日:2004-12-24
申请人: Takao Nakajima , Masamori Sugawara , Shin-ichi Uchida , Tetsuji Ohno , Yuji Nomoto , Noriaki Uesaka , Yoshisuke Nakasato
发明人: Takao Nakajima , Masamori Sugawara , Shin-ichi Uchida , Tetsuji Ohno , Yuji Nomoto , Noriaki Uesaka , Yoshisuke Nakasato
IPC分类号: A61K31/427 , C07D417/14
CPC分类号: C07D417/06 , A61K31/427 , A61K31/438 , A61K31/4439 , A61K31/444 , A61K31/454 , A61K31/4725 , A61K31/496 , A61K31/497 , A61K31/4985 , A61K31/501 , A61K31/506 , A61K31/5383 , A61K31/541 , A61K31/542 , A61K31/551 , A61K31/553 , A61K31/695 , C07D417/04 , C07D417/14 , C07D491/048 , C07D491/10 , C07D498/04 , C07D513/04
摘要: (Wherein n is an integer of from 0 to 3; R1 is substituted or unsubstituted cycloalkyl, substituted or unsubstituted aryl, a substituted or unsubstituted alicyclic heterocyclic group, or a substituted or unsubstituted aromatic heterocyclic group; R2 is halogen, substituted or unsubstituted lower alkyl, substituted or unsubstituted aryl, a substituted or unsubstituted alicyclic heterocyclic group, a substituted or unsubstituted aromatic heterocyclic group, —COR8, or the like; R3 and R4 may be the same or different, and each represents a hydrogen atom, substituted or unsubstituted lower alkyl, substituted or unsubstituted aralkyl, —COR12, or the like)For example, provided are adenosine A2A receptor antagonists comprising, as the active ingredient, a thiazole derivative represented by a general formula (I), or a pharmaceutically acceptable salt thereof, and the like.
摘要翻译: 本发明提供的腺苷A 2A受体拮抗剂包含作为活性成分的由通式(I)表示的噻唑衍生物或其药学上可接受的盐:......(其中n为0-3的整数; R 1为取代或 取代或未取代的芳基,取代或未取代的脂环族杂环基或取代或未取代的芳族杂环基; R2为卤素,取代或未取代的低级烷基,取代或未取代的芳基,取代或未取代的脂环族杂环基, 或未取代的芳族杂环基,-COR 8等; R 3和R 4可以相同或不同,各自表示氢原子,取代或未取代的低级烷基,取代或未取代的芳烷基,-COR 12等)。
-
-
-
-
-
-
-
-
-